Virtu Financial LLC Otonomy, Inc. Transaction History

Virtu Financial LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	BUY	$1.72 - $2.51 $20,741 - $30,268	12,059 Added 85.82%	26,111 $54,000
Q1 2022 May 17, 2022	BUY	$1.72 - $2.47 $6,100 - $8,761	3,547 Added 33.76%	14,052 $34,000
Q4 2021 Feb 17, 2022	BUY	$1.69 - $2.31 $17,753 - $24,266	10,505 New	10,505 $22,000
Q3 2021 Nov 12, 2021	SELL	$1.22 - $2.2 $84,367 - $152,138	-69,154 Closed	0 $0
Q2 2021 Sep 17, 2021	BUY	$2.06 - $2.67 $142,457 - $184,641	69,154 New	69,154 $154,000
Q3 2018 Nov 13, 2018	SELL	$2.6 - $3.95 $32,929 - $50,026	-12,665 Closed	0 $0
Q2 2018 Jul 30, 2018	SELL	$3.7 - $4.75 $52,536 - $67,445	-14,199 Reduced 52.86%	12,665 $49,000
Q2 2018 Jul 30, 2018	BUY	$3.7 - $4.75 $55,400 - $71,121	14,973 Added 125.92%	26,864 $104,000
Q1 2018 May 14, 2018	SELL	$4.05 - $6.1 $52,168 - $78,574	-12,881 Reduced 52.0%	11,891 $50,000
Q4 2017 Feb 09, 2018	SELL	$2.8 - $5.55 $215,160 - $426,478	-76,843 Reduced 75.62%	24,772 $137,000
Q3 2017 Nov 15, 2017	BUY	$3.2 - $20.8 $325,168 - $2.11 Million	101,615	101,615 $41,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.